Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

Regeneron和Illumina加入了对健康数据专家Truveta的重大投资，该投资将支持创建一个重大的新基因组计划。

The two companies, along with 17 US health systems, will collectively take a $320 million stake in Truveta, with Regeneron putting up the lion's share (almost $120 million) while Illumina is contributing $20 million to its Series C.

这两家公司以及17家美国医疗系统公司将共同持有Truveta 3.2亿美元的股份，其中Regeneron占最大份额（近1.2亿美元），而Illumina为其C系列贡献了2000万美元。

The cash injection will go towards the Truveta Genome Project, which aims to compile genetic data on tens of millions of consented and de-identified volunteers to create what will be 'the largest and most diverse database of genotypic and phenotypic information ever assembled,' claims the company.

该公司称，这笔资金将用于Truveta基因组计划，该计划旨在收集数千万已获得同意并被取消身份的志愿者的遗传数据，以创建“有史以来最大、最多样化的基因型和表型信息数据库”。

It will tap into Truveta's

它将进入Truveta的

platform

平台

– based on electronic medical record

–基于电子病历

data

数据

and updated daily – which covers more than 120 million people in the US, harvesting anonymised patient care information from tens of thousands of clinical care sites across most states.

每日更新-覆盖美国1.2亿多人，从大多数州的数万个临床护理网站收集匿名患者护理信息。

The Regeneron Genetics Centre (RGC) will use leftover biospecimens from routine lab tests to sequence up to ten million exomes – all of the exons in a genome that code for proteins – which according to the biopharma company will 'accelerate drug discovery and transform patient care.'

Regeneron遗传学中心（RGC）将使用常规实验室测试中剩余的生物样本对多达1000万个外显子组进行测序，这些外显子组是基因组中编码蛋白质的所有外显子，据生物制药公司称，这些外显子将“加速药物发现并改变患者护理”

After the initial sequencing, the biospecimens will be stored to support future multi-omics sequencing studies, while Truveta and its partners will also use the data to advance drug discovery, improve clinical trials, and train artificial intelligence models.

初始测序后，将存储生物样本以支持未来的多组学测序研究，而Truveta及其合作伙伴也将使用这些数据来推进药物发现，改进临床试验并训练人工智能模型。

The announcement comes hard on the heels of another population-based study involving the RGC. Last week, a major

在RGC参与的另一项基于人群的研究之后，这一宣布来得很艰难。上周，一个主要

population proteomics study

群体蛋白质组学研究

using UK Biobank patient samples, backed by 14 pharma companies, got underway on 600,000 patient samples.

使用由14家制药公司支持的英国生物银行患者样本，对60万患者样本进行了研究。

'Just like volunteering to be an organ donor on your driver's license is a simple act of service with a profound impact, the Truveta Genome Project enables each of us to anonymously contribute to dramatically accelerate progress in discovering the science of humanity, improving the health of our families and communities, and lowering the cost of care,' commented Truveta's co-founder and chief executive Terry Myerson..

Truveta的联合创始人兼首席执行官特里·迈尔森（TerryMyerson）评论道：“就像自愿在驾驶执照上成为器官捐赠者是一种简单的服务行为，具有深远的影响一样，Truveta基因组计划使我们每个人都能够匿名地为显着加速人类科学的发现、改善家庭和社区的健康以及降低护理成本做出贡献。”。。

'Discoveries from smaller datasets have led to important new approaches to help prevent heart disease and restore hearing in children with certain forms of congenital deafness – it is so exciting to envision where a complete representative genomic dataset will guide us.'

“来自较小数据集的发现带来了重要的新方法，有助于预防某些先天性耳聋儿童的心脏病和恢复听力-设想一个完整的代表性基因组数据集将指导我们是如此令人兴奋。”

Regeneron said RGC will have exclusive rights to perform all research-related sequencing on samples collected under the collaboration, in addition to access to the de-identified electronic health record (HER) data provided by each of the consented study participants.

Regeneron表示，RGC将拥有对合作收集的样本进行所有与研究相关的测序的专有权利，此外还可以访问每个同意的研究参与者提供的未识别的电子健康记录（HER）数据。

Meanwhile, Regeneron and Truveta said they plan to use the data in the development of new approaches for healthcare delivery and population health management.

与此同时，Regeneron和Truveta表示，他们计划将这些数据用于开发医疗保健和人口健康管理的新方法。

'By combining Regeneron's expertise in genetics and drug development with Truveta's extensive phenotypic data and collaboration of leading US health systems, we hope to create the 'big data' that will empower the next generation of drug discovery, as well as enable new approaches to healthcare analytics and healthcare management,' remarked Regeneron's chief scientific officer George Yancopoulos..

“通过将Regeneron在遗传学和药物开发方面的专业知识与Truveta的广泛表型数据以及与美国领先卫生系统的合作相结合，我们希望创建“大数据”，为下一代药物发现提供支持，并为医疗保健分析和医疗保健管理提供新方法，”Regeneron的首席科学官乔治·扬科波洛斯（GeorgeYancopoulos）表示。。